Invesaro

Stocks Comparison

Dexcom vs Stryker: revenue, profit, margins and growth compared

Dexcom brought in $4.7B of revenue in fiscal 2025, Stryker $25.1B in fiscal 2025. Revenue changed by +15.6% at Dexcom and +11.2% at Stryker on the year before, so Dexcom grew faster. Dexcom kept 17.9% of its revenue as net profit, Stryker 12.9%. Free cash flow was $1.1B at Dexcom and $4.3B at Stryker.

Side by side, latest fiscal year

DXCMSYK
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$4.7B$25.1B
Revenue growth+15.6%+11.2%
Net income$836.3M$3.2B
Net margin17.9%12.9%
Free cash flow$1.1B$4.3B
Free cash flow margin23.1%17.1%
Earnings per share (diluted)$2.09$8.40
Cash$917.7M$4B
Debtn/a$14.9B
Price to earnings41.432.4
Market value$32.7B$104.5B
Dividend yieldn/an/a
Rank by revenue in sector#65 of 523 · Health care#24 of 523 · Health care

Over the years

Revenue
DXCM FY2018: $1BDXCM FY2019: $1.5BDXCM FY2020: $1.9BDXCM FY2021: $2.4BDXCM FY2022: $2.9BDXCM FY2023: $3.6BDXCM FY2024: $4BDXCM FY2025: $4.7BSYK FY2018: $13.6BSYK FY2019: $14.9BSYK FY2020: $14.4BSYK FY2021: $17.1BSYK FY2022: $18.4BSYK FY2023: $20.5BSYK FY2024: $22.6BSYK FY2025: $25.1BFY18FY19FY20FY21FY22FY23FY24FY25
DXCM $4.7BSYK $25.1B
Net income
DXCM FY2018: -$127.1MDXCM FY2019: $101.1MDXCM FY2020: $549.7MDXCM FY2021: $216.9MDXCM FY2022: $341.2MDXCM FY2023: $541.5MDXCM FY2024: $576.2MDXCM FY2025: $836.3MSYK FY2018: $3.6BSYK FY2019: $2.1BSYK FY2020: $1.6BSYK FY2021: $2BSYK FY2022: $2.4BSYK FY2023: $3.2BSYK FY2024: $3BSYK FY2025: $3.2BFY18FY19FY20FY21FY22FY23FY24FY25
DXCM $836.3MSYK $3.2B
Net margin
DXCM FY2018: -12.3%DXCM FY2019: 6.8%DXCM FY2020: 28.5%DXCM FY2021: 8.9%DXCM FY2022: 11.7%DXCM FY2023: 14.9%DXCM FY2024: 14.3%DXCM FY2025: 17.9%SYK FY2018: 26.1%SYK FY2019: 14.0%SYK FY2020: 11.1%SYK FY2021: 11.7%SYK FY2022: 12.8%SYK FY2023: 15.4%SYK FY2024: 13.2%SYK FY2025: 12.9%FY18FY19FY20FY21FY22FY23FY24FY25
DXCM 17.9%SYK 12.9%
Revenue growth
DXCM FY2019: +43.1%DXCM FY2020: +30.5%DXCM FY2021: +27.1%DXCM FY2022: +18.8%DXCM FY2023: +24.5%DXCM FY2024: +11.3%DXCM FY2025: +15.6%SYK FY2019: +9.4%SYK FY2020: -3.6%SYK FY2021: +19.2%SYK FY2022: +7.8%SYK FY2023: +11.1%SYK FY2024: +10.2%SYK FY2025: +11.2%FY19FY20FY21FY22FY23FY24FY25
DXCM +15.6%SYK +11.2%
Free cash flow
DXCM FY2018: $56.1MDXCM FY2019: $134.5MDXCM FY2020: $276.6MDXCM FY2021: $53.3MDXCM FY2022: $304.7MDXCM FY2023: $511.9MDXCM FY2024: $630.7MDXCM FY2025: $1.1BSYK FY2018: $2BSYK FY2019: $1.5BSYK FY2020: $2.8BSYK FY2021: $2.7BSYK FY2022: $2BSYK FY2023: $3.1BSYK FY2024: $3.5BSYK FY2025: $4.3BFY18FY19FY20FY21FY22FY23FY24FY25
DXCM $1.1BSYK $4.3B

Fiscal years as each company reports them; the two may end in different months.

Questions about Dexcom and Stryker

Which is bigger by revenue, Dexcom or Stryker?

Stryker is bigger by revenue: $25.1B in fiscal 2025, against $4.7B for Dexcom in fiscal 2025.

Which keeps more of its revenue as profit, Dexcom or Stryker?

Dexcom had a net margin of 17.9% in fiscal 2025; Stryker had 12.9% in fiscal 2025.

Which grew revenue faster, Dexcom or Stryker?

In their latest fiscal years revenue changed by +15.6% at Dexcom and +11.2% at Stryker.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies